As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol
and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of …

Awareness that the metabolic phenotype of cells within tumours is heterogeneous—and
distinct from that of their normal counterparts—is growing. In general, tumour cells …

Abstract The statin drugs ('statins') potently inhibit hydroxymethylglutaryl-coenzyme A (HMG-
CoA) reductase by competitively blocking the active site of the enzyme. Statins decrease de …

Metabolic reprogramming is one of the most important hallmarks of malignant tumors.
Specifically, lipid metabolic reprogramming has marked impacts on cancer progression and …

Cancer cells are highly dependent on different metabolic pathways for sustaining their
survival, growth, and proliferation. Lipid metabolism not only provides the energetic needs of …

Statins, a class of cholesterol-lowering medications that inhibit 3-hydroxy-3-methyl-glutaryl-
coenzyme A reductase, are commonly administered to treat atherosclerotic cardiovascular …

Background and Aims: Statins are the first-line medication to treating hypercholesterolemia.
Several studies have investigated the impact of statins on the risk of hepatocellular …

Abstract Statins [3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase,
abbreviated HMGCR) inhibitors], are well-known cholesterol-depleting agents. Since the …

Since reprogramming energy metabolism is considered a new hallmark of cancer, tumor
metabolism is again in the spotlight of cancer research. Many studies have been carried out …

MACC1 (Metastasis Associated in Colon Cancer 1) is a key driver and prognostic biomarker
for cancer progression and metastasis in a large variety of solid tumor types, particularly …